Publication | Open Access

Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1α), in patients with refractory solid tumors

Hypoxia-inducible Factor-1 AlphaOncologyMalignant DiseaseMedicinePathologyCancer Cell BiologyAntisense Oligonucleotide InhibitorMolecular OncologyRefractory Solid TumorsCancer TreatmentPharmacologyRadiation OncologyCancer Research